Review

line-scan function in (MetaMorph Inc)

About

News

Press Release

Team

Advisors

Partners

Contact

Bioz Stars

Bioz vStars

Buy from Supplier

Structured Review

MetaMorph Inc line-scan function in
Line Scan Function In, supplied by MetaMorph Inc, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/line-scan+function+in/linescan+function/pm39271061-367-22-25
Average 90 stars, based on 1 article reviews

line-scan function in - by Bioz Stars, 2026-09

90/100 stars

Images

other:

Article Title: The concerted actions of Tip1/CLIP-170, Klp5/Kinesin-8, and Alp14/XMAP215 regulate microtubule catastrophe at the cell end
Article Snippet: Intensity measurements were carried out with the line-scan function in MetaMorph along the selected targets in maximum projection images.

Article Title: Microtubules Accelerate the Kinase Activity of Aurora-B by a Reduction in Dimensionality
Article Snippet: The intensity of the CCA-GFP on microtubules was measured using the line-scan function in Metamorph.

Article Title: Dynamic microtubules regulate the local concentration of E-cadherin at cell-cell contacts.
Article Snippet: Levels of cadherin accumulation at cell-cell contacts were quantified from epi-illumination images using the line-scan function in MetaMorph (Verma et al., 2004).

Article Title: Multi-site fungicides suppress banana Panama disease, caused by Fusarium oxysporum f. sp. cubense Tropical Race 4.
Article Snippet: Intensity profiles TMRM fluorescence in germ tubes was done using the "line-scan" function in MetaMorph.

Article Title: New insights into the functions of ACBD4/5-like proteins using a combined phylogenetic and experimental approach across model organisms.
Article Snippet: To measure peroxisome distribution (GFP-SKL) in hyphal cells, the mean fluorescent intensity over the length of individual cells was measured using the line-scan function in MetaMorph.

Image Search Results

a Structural model of NOPLight and screening summary. n ≥ 3 cells for each variant. b Representative images of HEK293T cells (top; scale bars, 10 µm) and neurons (bottom; scale bars, 20 µm) expressing NOPLight before and after application of 1 µM N/OFQ and ΔF heat map. c Responses of NOPLight or NOPLight-ctr in HEK293T cell and neurons to 1 µM N/OFQ, followed by competition with 10 µM J-113397. d Quantification of maximal responses from ( c ), n = 38, 30, 22, 27 cells from three independent experiments, respectively. Data shown as mean ± SD. (One-sided Mann–Whitney U -test, **** P < 0.0001, P = 1.003 × 10 −12 , and 1.262 × 10 −9 for NOPLight versus NOPLight-ctr in HEK293T and neurons). e Normalized response of HEK293T cells and neurons expressing NOPLight to N/OFQ titrations (mean ± SD) fitted with three-parameter Hill equation. n = 3 independent experiments per concentration. f Line-scan time plot of NOPLight ΔF/F 0 (gray) from membrane-pixels shown in bottom. Right, quantification of time constant (τ) from four independent experiments. Data represented as mean ± SD. g Left: experimental schematics and images (scale bars, 20 µm), right: time plot of normalized ΔF/F 0 from a representative experiment (gray) with quantified time constant (τ off ). Data represented as mean ± SD. h Maximal NOPLight response to: NCS, Nocistatin; J11, J-113397; UFP, UFP-101; RO, Ro 64-6198; MCO, MCOPPB; OFQ1-11, Orphanin-FQ (1–11)). * P < 0.05, ** P < 0.01, P = 0.024, Nocistatin; 0.0012, J-113397; 0.0012, UFP-101. n = 9 cells except MCO ( n = 8) from three independent experiments. i Maximal NOPLight response to endogenous opioid ligands (1 µM). ** P < 0.01, P = 0.003, Dynorphin A; P = 0.003, Dynorphin-B; P = 0.003, Leu-Enkephalin; P = 0.003, Met-Enkephalin; P = 0.003, β-endorphin. n = 9 from three independent experiments. Statistical comparisons in ( h , i ) by one-sided pairwise Mann–Whitney rank test with post hoc Bonferroni correction, data represented as mean ± SEM. j NOPLight response to neurotransmitters (DA dopamine, ACh acetylcholine, GABA gamma-Aminobutyric, all 1 mM). n = 29 (DA) or 30 (ACh, GABA) cells from three independent experiments (two-sided paired t -test, **** P < 0.0001, P = 2.45 × 10 −22 , 7.46 × 10 −19 , and 7.82 × 10 −21 , respectively).

Journal: Nature Communications

Article Title: Development of a genetically encoded sensor for probing endogenous nociceptin opioid peptide release

doi: 10.1038/s41467-024-49712-0

Figure Lengend Snippet: a Structural model of NOPLight and screening summary. n ≥ 3 cells for each variant. b Representative images of HEK293T cells (top; scale bars, 10 µm) and neurons (bottom; scale bars, 20 µm) expressing NOPLight before and after application of 1 µM N/OFQ and ΔF heat map. c Responses of NOPLight or NOPLight-ctr in HEK293T cell and neurons to 1 µM N/OFQ, followed by competition with 10 µM J-113397. d Quantification of maximal responses from ( c ), n = 38, 30, 22, 27 cells from three independent experiments, respectively. Data shown as mean ± SD. (One-sided Mann–Whitney U -test, **** P < 0.0001, P = 1.003 × 10 −12 , and 1.262 × 10 −9 for NOPLight versus NOPLight-ctr in HEK293T and neurons). e Normalized response of HEK293T cells and neurons expressing NOPLight to N/OFQ titrations (mean ± SD) fitted with three-parameter Hill equation. n = 3 independent experiments per concentration. f Line-scan time plot of NOPLight ΔF/F 0 (gray) from membrane-pixels shown in bottom. Right, quantification of time constant (τ) from four independent experiments. Data represented as mean ± SD. g Left: experimental schematics and images (scale bars, 20 µm), right: time plot of normalized ΔF/F 0 from a representative experiment (gray) with quantified time constant (τ off ). Data represented as mean ± SD. h Maximal NOPLight response to: NCS, Nocistatin; J11, J-113397; UFP, UFP-101; RO, Ro 64-6198; MCO, MCOPPB; OFQ1-11, Orphanin-FQ (1–11)). * P < 0.05, ** P < 0.01, P = 0.024, Nocistatin; 0.0012, J-113397; 0.0012, UFP-101. n = 9 cells except MCO ( n = 8) from three independent experiments. i Maximal NOPLight response to endogenous opioid ligands (1 µM). ** P < 0.01, P = 0.003, Dynorphin A; P = 0.003, Dynorphin-B; P = 0.003, Leu-Enkephalin; P = 0.003, Met-Enkephalin; P = 0.003, β-endorphin. n = 9 from three independent experiments. Statistical comparisons in ( h , i ) by one-sided pairwise Mann–Whitney rank test with post hoc Bonferroni correction, data represented as mean ± SEM. j NOPLight response to neurotransmitters (DA dopamine, ACh acetylcholine, GABA gamma-Aminobutyric, all 1 mM). n = 29 (DA) or 30 (ACh, GABA) cells from three independent experiments (two-sided paired t -test, **** P < 0.0001, P = 2.45 × 10 −22 , 7.46 × 10 −19 , and 7.82 × 10 −21 , respectively).

Article Snippet: Fluorescent signals were excited at 488 nm (NOPLight) and 561 nm (Red-Dextran dye) and recorded using the high-speed line-scan function (Zeiss LSM 800) at 800 Hz.

Techniques: Variant Assay, Expressing, MANN-WHITNEY, Concentration Assay, Membrane

a Expression of NOPLight in the ARC. Scale bar, 200 µm. Insets, scale bars, 50 µm. b – f Change in NOPLight fluorescence measured in ARC neurons in response to bath-applied N/OFQ or release of chemogenetically-activated PNOC neurons. Fluorescence was detected from 0.15–0.2 mm 2 ROIs. Each experiment was performed in a different brain slice. b NOPLight responses of a single ROI to increasing N/OFQ concentrations. c Concentration-response relation showing N/OFQ effect on the fluorescence of NOPLight (black) and NOPLight-Ctr (gray) -expressing cells in the ARC. Data represented as mean ± SEM. Inset, mean fluorescence increases in response to different concentrations of N/OFQ. Color-code as in ( b ). d Experimental schematic for chemogenetic experiments in brain slices. e Representative immunohistochemical image showing DREADD (hM3Dq) expression in PNOC neurons of the ARC as well as pan-neuronal expression of NOPLight. Scale bar, 100 µm. Magnification is shown on the right. Scale bar, 20 µm. f Perforated patch-clamp recordings from a hM3Dq-expressing PNOC neuron showing the effect of 10 min CNO application (3 µM) on action potential frequency. Left, rate histogram (bin width 60 s). Right, representative sections of the original recording correspond to the times indicated by the blue and red color codes. g – i Changes (mean ± SEM) in NOPLight fluorescence measured in the ARC in response to activation of hM3Dq-expressing PNOC neurons by 10 min bath application of 3 µM clozapine-N-oxide (CNO) ( g ) and 100 nM and 500 nM N/OFQ ( h ). g Upper and lower are the same data: traces in the upper panel are aligned to the CNO application, and traces in the lower panel are aligned to the response onset. Recordings in ( g , h ) were performed from the same brain slices. Bars indicate the application of CNO and N/OFQ, respectively. Scale bars apply to ( g , h ). i Maximal fluorescence changes upon applications of CNO and N/OFQ, respectively. The box represents the interquartile range, indicating the 25th and 75th percentiles with a median marked by a horizontal line inside the box. Whiskers extend to the minimum and maximum values, excluding outliers (•). The numbers in brackets represent the number of experiments (brain slices). N values indicate the number of animals. Data represented as mean ± SEM.

Journal: Nature Communications

Article Title: Development of a genetically encoded sensor for probing endogenous nociceptin opioid peptide release

doi: 10.1038/s41467-024-49712-0

Figure Lengend Snippet: a Expression of NOPLight in the ARC. Scale bar, 200 µm. Insets, scale bars, 50 µm. b – f Change in NOPLight fluorescence measured in ARC neurons in response to bath-applied N/OFQ or release of chemogenetically-activated PNOC neurons. Fluorescence was detected from 0.15–0.2 mm 2 ROIs. Each experiment was performed in a different brain slice. b NOPLight responses of a single ROI to increasing N/OFQ concentrations. c Concentration-response relation showing N/OFQ effect on the fluorescence of NOPLight (black) and NOPLight-Ctr (gray) -expressing cells in the ARC. Data represented as mean ± SEM. Inset, mean fluorescence increases in response to different concentrations of N/OFQ. Color-code as in ( b ). d Experimental schematic for chemogenetic experiments in brain slices. e Representative immunohistochemical image showing DREADD (hM3Dq) expression in PNOC neurons of the ARC as well as pan-neuronal expression of NOPLight. Scale bar, 100 µm. Magnification is shown on the right. Scale bar, 20 µm. f Perforated patch-clamp recordings from a hM3Dq-expressing PNOC neuron showing the effect of 10 min CNO application (3 µM) on action potential frequency. Left, rate histogram (bin width 60 s). Right, representative sections of the original recording correspond to the times indicated by the blue and red color codes. g – i Changes (mean ± SEM) in NOPLight fluorescence measured in the ARC in response to activation of hM3Dq-expressing PNOC neurons by 10 min bath application of 3 µM clozapine-N-oxide (CNO) ( g ) and 100 nM and 500 nM N/OFQ ( h ). g Upper and lower are the same data: traces in the upper panel are aligned to the CNO application, and traces in the lower panel are aligned to the response onset. Recordings in ( g , h ) were performed from the same brain slices. Bars indicate the application of CNO and N/OFQ, respectively. Scale bars apply to ( g , h ). i Maximal fluorescence changes upon applications of CNO and N/OFQ, respectively. The box represents the interquartile range, indicating the 25th and 75th percentiles with a median marked by a horizontal line inside the box. Whiskers extend to the minimum and maximum values, excluding outliers (•). The numbers in brackets represent the number of experiments (brain slices). N values indicate the number of animals. Data represented as mean ± SEM.

Article Snippet: Fluorescent signals were excited at 488 nm (NOPLight) and 561 nm (Red-Dextran dye) and recorded using the high-speed line-scan function (Zeiss LSM 800) at 800 Hz.

Techniques: Expressing, Fluorescence, Slice Preparation, Concentration Assay, Immunohistochemical staining, Patch Clamp, Activation Assay

a Fiber photometry schematic. Cartoon of NOPLight viral injection and fiber implant in the VTA. b Representative image showing DAPI (blue) and NOPLight (green) expression with fiber placement. c Left: Averaged traces of NOPLight fluorescence after systemic (i.p.) injection of vehicle (veh, black; n = 11 mice) or 1, 5, or 10 mg/kg of selective NOPR agonist Ro 64-6198 (RO, green; n = 5, 12, or 16 mice/group, respectively). Right: Mean NOPLight fluorescence 20–25 min after RO injection increases dose-dependently (two-tailed Mann–Whitney test, ** p = 0.0012, **** p < 0.0001). Data represented as mean ± SEM. d Left: Averaged traces of NOPLight fluorescence after 10 mg/kg RO (pink), 10 mg/kg selective NOPR antagonist LY2940094 (LY, o.g., blue), or both (purple) ( n = 4 mice). Right: Increase in signal 20–25 min after RO is blocked by LY pretreatment (two-tailed Mann–Whitney test, * p = 0.0286, # p = 0.0286, n = 4 mice). Data represented as mean ± SEM. e Same as ( d ) for NOPR antagonist J-113397 (J11, i.p.) (two-tailed Mann–Whitney test, ## p = 0.0028, #### p < 0.0001, **** p < 0.0001, n = 9 mice, RO; 4 mice, J11; 9 mice, J11 + RO). Data represented as mean ± SEM. f Top: Cartoon of FLEX-NOPLight or NOPLight-ctr viral injection and fiber implant in the VTA. Bottom: Representative image showing expression of DAPI (blue) and FLEX-NOPLight (left, green) or NOPLight-ctr (right, green), with fiber placement in VTA. g Averaged traces of NOPLight (green), FLEX-NOPLight (blue), or NOPLight-ctr (gray) fluorescence ( n = 16, 3, 6 mice, respectively) after systemic (i.p.) injection of 10 mg/kg RO. Data represented as mean ± SEM. h Area under the curve (AUC) of each NOPLight variant after RO injection (two-tailed Mann–Whitney test, * p = 0.0275, *** p = 0.0001, **** p < 0.0001, ns not significant ( p = 0.9577), # p = 0.0238, #### p < 0.0001. Group sizes left to right: n = 11, 5, 12, 16, 3, and 6 mice). Data represented as mean ± SEM. PN paranigral VTA, veh vehicle, BL baseline.

Journal: Nature Communications

Article Title: Development of a genetically encoded sensor for probing endogenous nociceptin opioid peptide release

doi: 10.1038/s41467-024-49712-0

Figure Lengend Snippet: a Fiber photometry schematic. Cartoon of NOPLight viral injection and fiber implant in the VTA. b Representative image showing DAPI (blue) and NOPLight (green) expression with fiber placement. c Left: Averaged traces of NOPLight fluorescence after systemic (i.p.) injection of vehicle (veh, black; n = 11 mice) or 1, 5, or 10 mg/kg of selective NOPR agonist Ro 64-6198 (RO, green; n = 5, 12, or 16 mice/group, respectively). Right: Mean NOPLight fluorescence 20–25 min after RO injection increases dose-dependently (two-tailed Mann–Whitney test, ** p = 0.0012, **** p < 0.0001). Data represented as mean ± SEM. d Left: Averaged traces of NOPLight fluorescence after 10 mg/kg RO (pink), 10 mg/kg selective NOPR antagonist LY2940094 (LY, o.g., blue), or both (purple) ( n = 4 mice). Right: Increase in signal 20–25 min after RO is blocked by LY pretreatment (two-tailed Mann–Whitney test, * p = 0.0286, # p = 0.0286, n = 4 mice). Data represented as mean ± SEM. e Same as ( d ) for NOPR antagonist J-113397 (J11, i.p.) (two-tailed Mann–Whitney test, ## p = 0.0028, #### p < 0.0001, **** p < 0.0001, n = 9 mice, RO; 4 mice, J11; 9 mice, J11 + RO). Data represented as mean ± SEM. f Top: Cartoon of FLEX-NOPLight or NOPLight-ctr viral injection and fiber implant in the VTA. Bottom: Representative image showing expression of DAPI (blue) and FLEX-NOPLight (left, green) or NOPLight-ctr (right, green), with fiber placement in VTA. g Averaged traces of NOPLight (green), FLEX-NOPLight (blue), or NOPLight-ctr (gray) fluorescence ( n = 16, 3, 6 mice, respectively) after systemic (i.p.) injection of 10 mg/kg RO. Data represented as mean ± SEM. h Area under the curve (AUC) of each NOPLight variant after RO injection (two-tailed Mann–Whitney test, * p = 0.0275, *** p = 0.0001, **** p < 0.0001, ns not significant ( p = 0.9577), # p = 0.0238, #### p < 0.0001. Group sizes left to right: n = 11, 5, 12, 16, 3, and 6 mice). Data represented as mean ± SEM. PN paranigral VTA, veh vehicle, BL baseline.

Article Snippet: Fluorescent signals were excited at 488 nm (NOPLight) and 561 nm (Red-Dextran dye) and recorded using the high-speed line-scan function (Zeiss LSM 800) at 800 Hz.

Techniques: Injection, Expressing, Fluorescence, Two Tailed Test, MANN-WHITNEY, Variant Assay

a Schematic of fiber photometry setup. Coronal brain cartoon of fiber implant and viral co-injection of FLEX-NOPLight with either DIO-hM3D(Gq) or mCherry in the VTA of PNOC-Cre mice. b Left: Representative traces of FLEX-NOPLight fluorescence after systemic (i.p.) injection of 5 mg/kg clozapine-N-oxide (CNO) in hM3D(Gq) (light green) or mCherry control (dark green) animals. Right: Mean FLEX-NOPLight fluorescence 40–45 min after CNO injection is significantly elevated relative to the pre-injection baseline period (BL) in hM3D(Gq) (two-tailed Wilcoxon test, * p = 0.0391, n = 8 mice) but not control animals (two-tailed Wilcoxon test, p > 0.9999, ns not significant, n = 3 mice). Z-scores for each individual animal averaged at baseline, and 50–55 min are shown (gray lines). Data represented as mean ± SEM. c Left: FLEX-NOPLight fluorescence (green) averaged before injection of 5 mg/kg CNO (0–10 min), and in 5 min bins following injection. 10 mg/kg of selective NOPR antagonist LY2940094 (LY) was administered (o.g.) to the LY + CNO (purple) group 30 min prior to photometry recording (two-way repeated-measures ANOVA with Bonferroni’s post hoc test, * p = 0.0207 (40–45 min), ** p = 0.0094 (45–50 min) or 0.0024 (50–55 min), n = 8 mice, CNO; three mice, LY + CNO). Right: Area under the curve (AUC) of FLEX-NOPLight signal after CNO injection (cumulative, 45 min). Pretreatment with NOPR antagonist LY prevents CNO-induced increases in FLEX-NOPLight fluorescence (two-tailed Mann–Whitney test, # p = 0.0485, n = 8 mice, CNO; three mice, LY + CNO). Data represented as mean ± SEM.

Journal: Nature Communications

Article Title: Development of a genetically encoded sensor for probing endogenous nociceptin opioid peptide release

doi: 10.1038/s41467-024-49712-0

Figure Lengend Snippet: a Schematic of fiber photometry setup. Coronal brain cartoon of fiber implant and viral co-injection of FLEX-NOPLight with either DIO-hM3D(Gq) or mCherry in the VTA of PNOC-Cre mice. b Left: Representative traces of FLEX-NOPLight fluorescence after systemic (i.p.) injection of 5 mg/kg clozapine-N-oxide (CNO) in hM3D(Gq) (light green) or mCherry control (dark green) animals. Right: Mean FLEX-NOPLight fluorescence 40–45 min after CNO injection is significantly elevated relative to the pre-injection baseline period (BL) in hM3D(Gq) (two-tailed Wilcoxon test, * p = 0.0391, n = 8 mice) but not control animals (two-tailed Wilcoxon test, p > 0.9999, ns not significant, n = 3 mice). Z-scores for each individual animal averaged at baseline, and 50–55 min are shown (gray lines). Data represented as mean ± SEM. c Left: FLEX-NOPLight fluorescence (green) averaged before injection of 5 mg/kg CNO (0–10 min), and in 5 min bins following injection. 10 mg/kg of selective NOPR antagonist LY2940094 (LY) was administered (o.g.) to the LY + CNO (purple) group 30 min prior to photometry recording (two-way repeated-measures ANOVA with Bonferroni’s post hoc test, * p = 0.0207 (40–45 min), ** p = 0.0094 (45–50 min) or 0.0024 (50–55 min), n = 8 mice, CNO; three mice, LY + CNO). Right: Area under the curve (AUC) of FLEX-NOPLight signal after CNO injection (cumulative, 45 min). Pretreatment with NOPR antagonist LY prevents CNO-induced increases in FLEX-NOPLight fluorescence (two-tailed Mann–Whitney test, # p = 0.0485, n = 8 mice, CNO; three mice, LY + CNO). Data represented as mean ± SEM.

Article Snippet: Fluorescent signals were excited at 488 nm (NOPLight) and 561 nm (Red-Dextran dye) and recorded using the high-speed line-scan function (Zeiss LSM 800) at 800 Hz.

Techniques: Injection, Fluorescence, Control, Two Tailed Test, MANN-WHITNEY

a Fiber photometry schematic. Cartoon of viral injection of NOPLight and fiber implant in VTA of wild-type mice ( n = 7 mice). b Cartoon depicting head-fixed cued-sucrose setup and trial structure. c Averaged traces of NOPLight fluorescence following pretreatment with vehicle (veh, green) or 20 mg/kg NOPR antagonist J-113397 (J11, blue), aligned to tone onset (magenta, shaded). Data represented as mean ± SEM. d Average licks made during vehicle or J-113397 sessions (two-tailed Wilcoxon test, p = 0.1649, ns not significant, n = 7 mice). Data represented as mean ± SEM. e Heat maps of NOPLight fluorescence, rows correspond to trials averaged in ( c ) for vehicle (left) and J11 (right) sessions. f Area under the curve (AUC) for averaged traces from ( c ), calculated over 5-s intervals surrounding cued-sucrose events. Decrease in NOPLight fluorescence during 10% sucrose access (two-tailed Wilcoxon test, ** p = 0.0034, n = 7 mice) is blocked by J11 pretreatment (two-tailed Mann–Whitney test, ## p = 0.0022, n = 7 mice). Data represented as mean ± SEM. g Top: Fiber photometry schematic. Middle: Cartoon depicting fiber implant and viral injection of DIO-GCaMP6m, FLEX-NOPLight, or NOPLight-ctr into the VTA of PNOC-Cre, OPRL1-Cre, or WT mice, respectively. Bottom: Session trial structure. h Left: Averaged trace of pnVTA PNOC GCaMP6m activity during tail lift. Right: AUC for photometry trace calculated over 5-s intervals surrounding tail lift (two-tailed Wilcoxon test, *** p = 0.0002 (5–10 s) or 0.0003 (10–15 s); **** p < 0.0001, n = 4 mice). Data represented as mean ± SEM. i Left: Averaged traces of FLEX-NOPLight (green) and NOPLight-ctr (gray) fluorescence during the tail lift. Right: AUC for photometry traces calculated over 5-s intervals surrounding tail lift. FLEX-NOPLight fluorescence increases during tail lift (two-tailed Wilcoxon test, ** p = 0.0034 (0–5 s) or 0.0093 (5–10 s); n = 3 mice), NOPLight-ctr fluorescence remains unchanged (two-tailed Mann–Whitney test, # p = 0.0264 (0–5 s) or 0.0326 (5–10 s); n = 8 mice, NOPLight-ctr; 3 mice, FLEX-NOPLight). Data represented as mean ± SEM. VITI variable inter-trial interval.

Journal: Nature Communications

Article Title: Development of a genetically encoded sensor for probing endogenous nociceptin opioid peptide release

doi: 10.1038/s41467-024-49712-0

Figure Lengend Snippet: a Fiber photometry schematic. Cartoon of viral injection of NOPLight and fiber implant in VTA of wild-type mice ( n = 7 mice). b Cartoon depicting head-fixed cued-sucrose setup and trial structure. c Averaged traces of NOPLight fluorescence following pretreatment with vehicle (veh, green) or 20 mg/kg NOPR antagonist J-113397 (J11, blue), aligned to tone onset (magenta, shaded). Data represented as mean ± SEM. d Average licks made during vehicle or J-113397 sessions (two-tailed Wilcoxon test, p = 0.1649, ns not significant, n = 7 mice). Data represented as mean ± SEM. e Heat maps of NOPLight fluorescence, rows correspond to trials averaged in ( c ) for vehicle (left) and J11 (right) sessions. f Area under the curve (AUC) for averaged traces from ( c ), calculated over 5-s intervals surrounding cued-sucrose events. Decrease in NOPLight fluorescence during 10% sucrose access (two-tailed Wilcoxon test, ** p = 0.0034, n = 7 mice) is blocked by J11 pretreatment (two-tailed Mann–Whitney test, ## p = 0.0022, n = 7 mice). Data represented as mean ± SEM. g Top: Fiber photometry schematic. Middle: Cartoon depicting fiber implant and viral injection of DIO-GCaMP6m, FLEX-NOPLight, or NOPLight-ctr into the VTA of PNOC-Cre, OPRL1-Cre, or WT mice, respectively. Bottom: Session trial structure. h Left: Averaged trace of pnVTA PNOC GCaMP6m activity during tail lift. Right: AUC for photometry trace calculated over 5-s intervals surrounding tail lift (two-tailed Wilcoxon test, *** p = 0.0002 (5–10 s) or 0.0003 (10–15 s); **** p < 0.0001, n = 4 mice). Data represented as mean ± SEM. i Left: Averaged traces of FLEX-NOPLight (green) and NOPLight-ctr (gray) fluorescence during the tail lift. Right: AUC for photometry traces calculated over 5-s intervals surrounding tail lift. FLEX-NOPLight fluorescence increases during tail lift (two-tailed Wilcoxon test, ** p = 0.0034 (0–5 s) or 0.0093 (5–10 s); n = 3 mice), NOPLight-ctr fluorescence remains unchanged (two-tailed Mann–Whitney test, # p = 0.0264 (0–5 s) or 0.0326 (5–10 s); n = 8 mice, NOPLight-ctr; 3 mice, FLEX-NOPLight). Data represented as mean ± SEM. VITI variable inter-trial interval.

Article Snippet: Fluorescent signals were excited at 488 nm (NOPLight) and 561 nm (Red-Dextran dye) and recorded using the high-speed line-scan function (Zeiss LSM 800) at 800 Hz.

Techniques: Injection, Fluorescence, Two Tailed Test, MANN-WHITNEY, Activity Assay

a . Fiber photometry schematic. Cartoon of NOPLight viral injection and fiber implant in the VTA of WT mice ( n = 4 mice). Representative image showing expression of DAPI (blue) and NOPLight (green) with fiber placement in VTA. b . Left: Cartoon depicting operant box setup for the progressive ratio (PR) test. Right: Trial structure for reward delivery during the paradigm. c . Top: Averaged trace of NOPLight signal for all mice ( n = 4), aligned to rewarded active nose pokes (ANPs) made during the PR test. Epoch includes the 5 s light cue (yellow, shaded) that precedes reward delivery. Time to pellet retrieval and duration of consumption period averaged across all trials (brown, shaded). Data represented as mean ± SEM. Bottom: Heat map, each row corresponds to a single, rewarded ANP epoch. d Top: Averaged trace of NOPLight signal for all mice ( n = 4), aligned to non-rewarded ANPs made during the PR test. Data represented as mean ± SEM. Bottom: Heat map, each row corresponds to a single, non-rewarded ANP epoch. e NOPLight fluorescence averaged over 5-s intervals for rewarded (green) and non-rewarded (blue) ANP epochs. Time to pellet retrieval and duration of consumption period averaged across all rewarded trials (brown, shaded). Across rewarded ANP trials, NOPLight signal decreases during reward consumption then immediately increases post-consumption relative to NOPLight signal measured during non-rewarded ANP epochs (two-way repeated-measures ANOVA with Bonferroni’s post hoc test, * p = 0.0122, ** p = 0.0033, *** p = 0.0003, n = 4 mice). Data represented as mean ± SEM. f , g Area under the curve (AUC) for photometry traces from c and d , respectively, calculated over 5-s intervals surrounding ( f ) rewarded ANPs (two-tailed Wilcoxon test, * p = 0.0125 (25–30 s) or 0.031 (30–35 s); ** p = 0.007 (5–10 s) or 0.0042 (15–20 s); *** p = 0.0008 (10–15 s); n = 4 mice) and ( g ) non-rewarded ANPs (two-tailed Wilcoxon test, * p = 0.0128 (5–10 s), **** p < 0.0001 (0–5 s), n = 4 mice). Data represented as mean ± SEM.

Journal: Nature Communications

Article Title: Development of a genetically encoded sensor for probing endogenous nociceptin opioid peptide release

doi: 10.1038/s41467-024-49712-0

Figure Lengend Snippet: a . Fiber photometry schematic. Cartoon of NOPLight viral injection and fiber implant in the VTA of WT mice ( n = 4 mice). Representative image showing expression of DAPI (blue) and NOPLight (green) with fiber placement in VTA. b . Left: Cartoon depicting operant box setup for the progressive ratio (PR) test. Right: Trial structure for reward delivery during the paradigm. c . Top: Averaged trace of NOPLight signal for all mice ( n = 4), aligned to rewarded active nose pokes (ANPs) made during the PR test. Epoch includes the 5 s light cue (yellow, shaded) that precedes reward delivery. Time to pellet retrieval and duration of consumption period averaged across all trials (brown, shaded). Data represented as mean ± SEM. Bottom: Heat map, each row corresponds to a single, rewarded ANP epoch. d Top: Averaged trace of NOPLight signal for all mice ( n = 4), aligned to non-rewarded ANPs made during the PR test. Data represented as mean ± SEM. Bottom: Heat map, each row corresponds to a single, non-rewarded ANP epoch. e NOPLight fluorescence averaged over 5-s intervals for rewarded (green) and non-rewarded (blue) ANP epochs. Time to pellet retrieval and duration of consumption period averaged across all rewarded trials (brown, shaded). Across rewarded ANP trials, NOPLight signal decreases during reward consumption then immediately increases post-consumption relative to NOPLight signal measured during non-rewarded ANP epochs (two-way repeated-measures ANOVA with Bonferroni’s post hoc test, * p = 0.0122, ** p = 0.0033, *** p = 0.0003, n = 4 mice). Data represented as mean ± SEM. f , g Area under the curve (AUC) for photometry traces from c and d , respectively, calculated over 5-s intervals surrounding ( f ) rewarded ANPs (two-tailed Wilcoxon test, * p = 0.0125 (25–30 s) or 0.031 (30–35 s); ** p = 0.007 (5–10 s) or 0.0042 (15–20 s); *** p = 0.0008 (10–15 s); n = 4 mice) and ( g ) non-rewarded ANPs (two-tailed Wilcoxon test, * p = 0.0128 (5–10 s), **** p < 0.0001 (0–5 s), n = 4 mice). Data represented as mean ± SEM.

Article Snippet: Fluorescent signals were excited at 488 nm (NOPLight) and 561 nm (Red-Dextran dye) and recorded using the high-speed line-scan function (Zeiss LSM 800) at 800 Hz.

Techniques: Injection, Expressing, Fluorescence, Two Tailed Test

Review

line-scan function in (MetaMorph Inc)

Structured Review

Images

Related Articles

other:

Similar Products

Image Search Results